Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.

Autor: Dabbous HM; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Abd-Elsalam S; Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt. sherif.abdelbaky@med.tanta.edu.ed., El-Sayed MH; Faculty of Medicine, Ain Shams University Research Institute-Clinical Research Center (MASRI-CRC), Cairo, Egypt., Sherief AF; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Ebeid FFS; Faculty of Medicine, Ain Shams University Research Institute-Clinical Research Center (MASRI-CRC), Cairo, Egypt., El Ghafar MSA; Department of Anesthesia, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Soliman S; Public Health and Community Medicine, Menoufia University, Menoufia, Egypt., Elbahnasawy M; Emergency Medicine and Traumatology Department, Faculty of Medicine, Tanta University, Tanta, Egypt., Badawi R; Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, El-Giash Street, Tanta, 31527, Egypt., Tageldin MA; Department of Chest Diseases, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Jazyk: angličtina
Zdroj: Archives of virology [Arch Virol] 2021 Mar; Vol. 166 (3), pp. 949-954. Date of Electronic Publication: 2021 Jan 25.
DOI: 10.1007/s00705-021-04956-9
Abstrakt: No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295.
Databáze: MEDLINE
Externí odkaz: